Current Report Filing (8-k)
September 09 2016 - 4:11PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of Earliest Event Reported):
September
9, 2016 (September 9, 2016)
PetLife
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-52445
|
|
33-1133537
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
38
West Main Street, Hancock, MD 21750
|
|
90210
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (844) 473-8543
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
1.01. Entry into Material Definitive Agreement
On
July 20, 2016, Petlife Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger with its wholly-owned subsidiary, PetLife
Merger Subsidiary, Inc., a Nevada Corporation, with PetLife Merger Subsidiary, Inc. being the surviving entity. As part of that
merger, the name of the Petlife Merger Subsidiary was changed back to PetLife Pharmaceuticals, Inc. The purpose of the subsidiary
merger was to effectuate a 1 for 5 reverse exchange of Petlife’s common stock pursuant to the terms of the merger. The combined
entities continue on public markets pursuant to Rule 12g-3 of the Securities Exchange Act of 1934, as amended.
That
corporate action has been reviewed by the Financial Industry Regulatory Authority (“FINRA”) and they have advised
that the action will be effectuated on public markets on Monday, September 12, 2016.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
PETLIFE
PHARMACEUTICALS, INC.
(Registrant)
Dated:
September 9, 2016
|
By:
|
/s/
Ralph T. Salvagno, MD
|
|
|
Ralph
T. Salvagno, MD
|
|
|
Chief
Executive Officer
|
Petlife Pharmaceuticals (CE) (USOTC:PTLF)
Historical Stock Chart
From Sep 2024 to Oct 2024
Petlife Pharmaceuticals (CE) (USOTC:PTLF)
Historical Stock Chart
From Oct 2023 to Oct 2024